IOVANCE BIOTHERAPEUTICS, INC. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $5.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2024-02-28
- IOVANCE BIOTHERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2023 was $5.30M, a 0.00% change from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2022 was $5.30M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month |
|---|---|
| 2023-12-31 | $5.30M 10-K · filed 2024-02-28 |
| 2022-12-31 | $5.30M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |